

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

**【Cover】**

<b>【Document Submitted】</b>	Extraordinary Report
<b>【Submitted to】</b>	Director, Kanto Local Finance Bureau
<b>【Date of Submission】</b>	June 23, 2023
<b>【Company Name】</b>	Ono Yakuhin Kogyo Kabushiki-Kaisha
<b>【Company Name (in English)】</b>	ONO PHARMACEUTICAL CO., LTD.
<b>【Position and Name of Representative】</b>	Gyo Sagara, President, Representative Director, and Chief Executive Officer
<b>【Location of Head Office】</b>	1-5, Doshomachi 2-chome, Chuo-ku, Osaka, Japan (The above is the location of the registered head office. The actual head office operations are located at 8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, Japan.)
<b>【Phone No.】</b>	Not applicable
<b>【Contact for Communications】</b>	Not applicable
<b>【Nearest Contact】</b>	8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, Japan
<b>【Phone No.】</b>	+81-(0)6-6263-5670
<b>【Contact for Communications】</b>	Kazuhiro Nagahama, Senior Director, Finance & Accounting
<b>【Place Where Available for Public Inspection】</b>	Tokyo Stock Exchange, Inc. (2-1 Nihombashi Kabutocho, Chuo-ku, Tokyo, Japan)

## 1 【Reason for Filing】

As the following proposals were resolved at the 75th Ordinary General Shareholders' Meeting of Ono Pharmaceutical Co., Ltd. (the "Company") held on June 22, 2023, the Company hereby files this Extraordinary Report pursuant to the provisions of Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and the provisions of Article 19, Paragraph 2, Item 9-2 of the Cabinet Office Ordinance on the Disclosure of Corporate Affairs, etc.

## 2 【Description of Report】

### (1) Date of the Ordinary General Shareholders' Meeting

June 22, 2023

### (2) Details of Proposals Resolved

#### Proposal 1 Appropriation of Surplus

##### Year-End Dividend

##### ① Type of dividend property

Cash

##### ② Allocation of dividend property to shareholders and total amount of such allocation

¥37 per share of common stock      Total dividend amount: ¥18,070,772,102

##### ③ Effective date of the distribution of the dividend

June 23, 2023

#### Proposal 2 Election of Seven (7) Members of the Board of Directors

Seven (7) Members of the Board of Directors, namely, Gyo Sagara, Toshihiro Tsujinaka, Toichi Takino, Kiyooki Idemitsu, Masao Nomura, Akiko Okuno and Shusaku Nagae were elected.

#### Proposal 3 Election of Two (2) Audit & Supervisory Board Members

Two (2) Audit & Supervisory Board Members, namely, Hironobu Tanisaka and Akiko Tanabe were elected.

#### Proposal 4 Revision to the Amount of Remuneration for Audit & Supervisory Board Members

The maximum amount of remuneration for Audit & Supervisory Board Members was revised to 150 million yen per year.

(3) The number of voting rights either approving, disapproving or abstaining on proposals resolved; requirements for the approval of the resolutions and their results

Proposal	For (Number of voting rights)	Against (Number of voting rights)	Abstentions (Number of abstentions)	Requirements for approval	Results Approval ratio (%)
Proposal 1 Appropriation of Surplus	4,212,901	10,807	1,424	(Note 1)	Approved 99.662
Proposal 2 Election of Seven (7) Members of the Board of Directors					
Gyo Sagara	3,993,125	217,391	14,624	(Note 2)	Approved 94.462
Toshihiro Tsujinaka	4,134,602	75,915	14,624		Approved 97.809
Toichi Takino	4,134,600	75,917	14,624		Approved 97.809
Kiyoaki Idemitsu	4,134,566	75,951	14,624		Approved 97.808
Masao Nomura	4,198,529	25,188	1,429		Approved 99.321
Akiko Okuno	4,206,173	18,968	5		Approved 99.502
Shusaku Nagae	4,199,567	24,150	1,429		Approved 99.346
Proposal 3 Election of Two (2) Audit & Supervisory Board Members				(Note 2)	
Hironobu Tanisaka	4,015,189	209,948	5	Approved 94.984	
Akiko Tanabe	4,218,664	6,484	5	Approved 99.798	
Proposal 4 Revision to the Amount of Remuneration for Audit & Supervisory Board Members	4,218,000	5,179	1,988	(Note 1)	Approved 99.782

Notes) 1. Proposal 1 and Proposal 4 require approval by a majority of voting rights of the shareholders in attendance eligible for exercising voting rights.

2. Proposal 2 and Proposal 3 require the attendance of shareholders holding one-third or more of voting rights owned by shareholders eligible for exercising voting rights and approval by the majority of said voting rights.

(4) The reason why a portion of the voting rights held by the shareholders in attendance at the Ordinary General Shareholders' Meeting was not counted

Resolutions of all the proposals have been legitimately reached in accordance with the Companies Act, as the requirements for approval have been met based on the number of confirmed votes of approval or disapproval by counting the voting rights exercised up to the day before this General Shareholders' Meeting and those of shareholders in attendance. Therefore, voting rights of the shareholders in attendance which are not confirmed as to whether they are approving, disapproving, or abstaining are not included in the count.